Production (Stage)
Calidi Biotherapeutics, Inc.
CLDI
$0.3198
-$0.0002-0.06%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.27% | -28.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.73% | -22.96% | |||
| Operating Income | -25.73% | 22.96% | |||
| Income Before Tax | -22.05% | 18.24% | |||
| Income Tax Expenses | 0.00% | 400.00% | |||
| Earnings from Continuing Operations | -22.03% | 18.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 49.02% | 240.00% | |||
| Net Income | -21.70% | 18.94% | |||
| EBIT | -25.73% | 22.96% | |||
| EBITDA | -26.55% | 23.34% | |||
| EPS Basic | 31.31% | 58.51% | |||
| Normalized Basic EPS | 31.43% | 58.79% | |||
| EPS Diluted | 31.31% | 58.51% | |||
| Normalized Diluted EPS | 31.43% | 58.79% | |||
| Average Basic Shares Outstanding | 77.16% | 95.41% | |||
| Average Diluted Shares Outstanding | 77.16% | 95.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||